Drug Target
doi: 10.3389/fnut.2022.1007816 Received 31 July 2022 Accepted 12 October 2022 Published 01 November 2022 Volume 9 - 2022 Edited by Yannan Jin, De Montfort University, United Kingdom Reviewed by Mostafa Waly, Sultan Qaboos University, Oman
No serious adverse events, hospitalization, organ damage, or deaths have been documented in over 100 preclinical studies, even at doses 1,000 times higher than typical therapeutic use
Those research themes should not be converted into product-performance, cosmetic, health, or treatment claims
CORPORALIGHT claimed 1500 mg and returned 256 mg
The main limiting factor for vitamin C supplements is gastrointestinal tolerance, as excessive supplementation can cause loose stools